Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

13.94 -0.11 (-0.78%)

Streaming Delayed Price Updated: 10:45 AM EST, Feb 26, 2026 Add to My Watchlist

Price and Volume

Volume	24,652
Open	13.71
Bid (Size)	13.84 (200)
Ask (Size)	14.05 (200)
Prev. Close	14.05
Today's Range	13.58 - 13.95
52wk Range	7.080 - 20.90
Shares Outstanding	407,265,944
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Amarin (AMRN) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Amarin (AMRN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 ↗

February 25, 2026

Via Chartmill

Performance

YTD	+1.6%	+1.6%
1 Month	-10.4%	-10.4%
3 Month	-13.6%	-13.6%
6 Month	-9.9%	-9.9%
1 Year	+20.5%	+20.5%

More News

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

From Amarin Corporation plc

Via GlobeNewswire

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

February 23, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

February 11, 2026

From Amarin Corporation plc

Via GlobeNewswire

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Earnings Outlook For Amarin Corp ↗

October 28, 2025

Via Benzinga

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

January 09, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

January 08, 2026

From Amarin Corporation plc

Via GlobeNewswire

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

November 09, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

November 03, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Corp (NASDAQ:AMRN) Beats Q3 2025 Earnings and Revenue Estimates ↗

October 29, 2025

Via Chartmill

Amarin Reports Third Quarter 2025 Financial Results

October 29, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

October 27, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025

October 15, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

October 14, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

August 31, 2025

From Amarin Corporation plc

Via GlobeNewswire

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

August 30, 2025

From Amarin Corporation plc

Via GlobeNewswire

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

August 25, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Reports Second Quarter 2025 Financial Results

July 30, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

July 23, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA ↗

June 24, 2025

Via Benzinga

Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges ↗

June 24, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 24, 2025

Via Benzinga

Frequently Asked Questions

Is Amarin Corporation plc - American Depositary Shares publicly traded?

Yes, Amarin Corporation plc - American Depositary Shares is publicly traded.

What exchange does Amarin Corporation plc - American Depositary Shares trade on?

Amarin Corporation plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Amarin Corporation plc - American Depositary Shares?

The ticker symbol for Amarin Corporation plc - American Depositary Shares is AMRN on the Nasdaq Stock Market

What is the current price of Amarin Corporation plc - American Depositary Shares?

The current price of Amarin Corporation plc - American Depositary Shares is 13.94

When was Amarin Corporation plc - American Depositary Shares last traded?

The last trade of Amarin Corporation plc - American Depositary Shares was at 02/26/26 10:45 AM ET

What is the market capitalization of Amarin Corporation plc - American Depositary Shares?

The market capitalization of Amarin Corporation plc - American Depositary Shares is 5.68B

How many shares of Amarin Corporation plc - American Depositary Shares are outstanding?

Amarin Corporation plc - American Depositary Shares has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.